Restructuring Edition: The industry emerged from the J.P. Morgan Healthcare Conference feeling renewed confidence about deal-making and financing, but drug developers continue to run short on cash or cut programs and jobs before the money runs out, including Cara, PMV and Ikena.

A number of companies could soon find out whether the European Medicines Agency will back pan-EU marketing approval for their respective products.

The future of GenSight hangs in the balance following the decision to withdraw its application in Europe for Lumevoq, the company's gene therapy for Leber hereditary optic neuropathy, and worries over a rapidly diminishing cash pile.

A Phase III disappointment in a maintenance therapy setting for FLT3-mutated acute myeloid leukemia is yet another failed attempt by Astellas to add to Xospata’s label since US FDA approval in 2018.